Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiogenesis combines stem cell delivery tech with heart laser therapy:

This article was originally published in Clinica

Executive Summary

Cardiogenesis has completed the first cardiac revascularisation surgery involving the use of its angina-relieving heart laser therapy combined with its investigational stem cell delivery system. During a heart bypass operation, surgeons in China used the firm's Phoenix revascularisation delivery system to administer stem cells precisely to heart tissue surrounding the channels created by the firm's Transmyocardial Revascularisation laser; the channels are believed to promote the growth of new blood vessels. "The Phoenix delivery system is a priority development program for the company, which we expect to implement with both our surgical and percutaneous-laser myocardial revascularisation platforms," said Michael Quinn, the Foothill Ranch, California firm's chairman and CEO.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT050907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel